Tarsier Pharma Ltd. (TARX)
| Market Cap | 258.63M |
| Revenue (ttm) | n/a |
| Net Income | -5.07M +106.4% |
| EPS | -0.18 |
| Shares Out | 28.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TARX
Tarsier Pharma is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet need in blinding diseases of the eye with underlying inflammatory pathologies. Our dazdotuftide platform technology is a bio-inspired immunomodulator, designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops (TRS01) and intravitreal injections (TRS02).
Financial Performance
Financial StatementsNews
Tarsier Pharma 5M share IPO price range $8.00-$10.00
Konik Capital Partners, a division of T.R. Winston & Co., is acting as sole book running manager for the offering.
Tarsier Pharma IPO Registration Document (F-1)
Tarsier Pharma has filed to go public with an IPO on the NYSE American
Israel-based Phase 3 ocular diseases biotech Tarsier Pharma files for a $35 million US IPO
Tarsier Pharma, an Israel-based Phase 3 biotech developing steroid-free therapies for ocular diseases, filed on Tuesday with the SEC to raise up to $35 million in an initial public offering.